Join us at TNW Conference 2022 for insights into the future of tech →

The heart of tech

This article was published on September 3, 2014

Google-founded Calico teams up with AbbVie to research treatments for age-related diseases

Google-founded Calico teams up with AbbVie to research treatments for age-related diseases
Jackie Dove
Story by

Jackie Dove

Reporter

Jackie Dove was in charge of The Next Web's Creativity channel from February 2014 through October 2015. Jackie Dove was in charge of The Next Web's Creativity channel from February 2014 through October 2015.

Calico, the Google-founded research and development company with a healthcare focus on diseases of the aging, has announced a new collaboration with AbbVie, the biopharmaceutical research offshoot of Abbott Laboratories.

This R&D collaboration is designed to assist the companies with creating, developing and eventually marketing new therapies for age-related diseases, such as neurodegeneration and cancer.

Calico plans to build a new R&D facility in the San Francisco Bay Area to focus specifically on aging and the diseases associated with it, and both companies say they may invest up to $1.5 billion to accelerate the development of new drugs and therapies.

Calico will focus on drug discovery and development while AbbVie will support the marketing of such drugs and therapies.

Calico is run by Arthur D. Levinson, the former chairman and CEO of Genentech and Dr. Hal V. Barron, Genentech’s former chief medical officer.

➤ Calico | Abbvie